Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2014. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility (PDMRs) regarding their personal holdings of the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on shareholding changes resulting from a dividend reinvestment plan.
Material Changes
The filing details an increase in share interests for specific individuals following the reinvestment of the dividend paid on July 10, 2014. The transaction price was 1,564.125 pence per Ordinary Share. The specific increases were:
- Sir Andrew Witty: 3,816 shares
- Lady C Witty: 1,835 shares
- Mr I W Whyte: 240 shares
- Mrs V A Whyte: No shares acquired
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory disclosure of director share transactions in accordance with Disclosure and Transparency Rules 3.1.4R(1)(a) and (c).
Investor Verification Points
- Verify the dividend reinvestment price of 1,564.125 pence per share against market data for July 10, 2014.
- Confirm the total shareholding positions of Sir Andrew Witty and other named directors post-transaction.
- Review the company's broader financial results for the period, as this filing contains no operational or financial performance data.